$MRNA is a clean case study in fast biotech repricing. Wednesday's close was +177% to $174.38 on ~18x average volume, pushing market cap from ~$25B to ~$69B after Merck and Moderna's melanoma trial hit its primary and key secondary endpoints. Thursday gave back ~20% of that, normal price discovery once the gap gets absorbed, and the treatment is still investigational, not yet approved. Volatility stays elevated until the market settles on a fair multiple. Tradable on BingX as a perpetual. #BingX #Macro Insights# #Altcoin Season#